SGP
SpyGlass Pharma, Inc.
34.97
+0.79 (+2.31%)
52w low 17.06
39.92 high
78.3% of range
Open
33.52
High
35.53
Low
33.24
Prev Close
34.18
Volume
77.56K
Avg Vol 3M
110.56K
Market Cap
1.17B
Currency
USD
6 Month Trend
—
C--
Chg--
Gap--
Vol--
×avg--
σ--
SMA20--
SMA50--
SMA200--
RSI--
SPY--
DD--
Bench--
Sig--
Hist--
pinned · Esc to release
hover · click to pin · ← → step · drag to zoom · shift-drag to measure
—Context
- Move across the chart.
Company
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| Employees | 76 |
| Web | site ↗ |
Performance
1D
+2.31%
5D
+1.51%
1M
+40.67%
3M
+38.39%
6M
+46.81%
YTD
--
1Y
--
2Y
--
3Y
--
5Y
--
MAX
+24.89%
Valuation
| P/E Trailing | -- |
| P/E Forward | -12.43x |
| Price / Book | 5.03x |
| Price / Sales | -- |
| EV / EBITDA | -14.91x |
| EPS Trailing | -2.51 |
| Dividend Yield | 0.00% |
| Beta | -- |
Profitability
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -- |
| Return on Assets | -- |
| Revenue Growth | -- |
| Debt / Equity | 0.01x |
| Current Ratio | 25.06x |
Business
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was headquartered in 2019 and is based in Irvine, California.